Payment overview · 2025
General Payments
$900.71
60 reported records · 12 companies
Healthcare provider profile · identity verified
Ted Michael Faro, DO
Allopathic & Osteopathic Physicians|Family Medicine · HOT SPRINGS, AR · NPI 1184621294
Verified facts
What the public records show
CMS Open Payments records show Ted Michael Faro, DO received $900.71 in general payments during 2025 across 60 reported records.
AstraZeneca Pharmaceuticals LP accounted for 23.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Farxiga by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 197 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $215.53 | 23.9% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $168.02 | 18.6% | 19 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $165.77 | 18.4% | 11 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $72.13 | 8.0% | 4 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $60.44 | 6.7% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $50.19 | 5.6% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $43.96 | 4.9% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $38.49 | 4.3% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $32.84 | 3.6% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $19.10 | 2.1% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $17.46 | 1.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.78 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $900.71 | 60 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $198.61 | 13 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $123.50 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $94.71 | 11 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $73.78 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $72.13 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $69.46 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $68.69 | 7 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $60.44 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $50.19 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $50.19 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $43.96 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $43.96 | 2 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $41.42 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $38.49 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $19.10 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.25 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $17.46 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.78 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 86 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 197 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
54 | 19 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
86 | 21 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
197 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
94 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 463 | 111 |
| Levothyroxine Sodium | Levothyroxine Sodium | 411 | 105 |
| Atorvastatin Calcium | Atorvastatin Calcium | 376 | 113 |
| Pantoprazole Sodium | Pantoprazole Sodium | 312 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 310 | 86 |
| Omeprazole | Omeprazole | 279 | 74 |
| Gabapentin | Gabapentin | 259 | 73 |
| Hydrochlorothiazide | Hydrochlorothiazide | 225 | 65 |
| Losartan Potassium | Losartan Potassium | 222 | 64 |
| Potassium Chloride | Potassium Chloride | 222 | 61 |
| Lisinopril | Lisinopril | 213 | 62 |
| Tizanidine Hcl | Tizanidine Hcl | 207 | 60 |
| Mounjaro | Tirzepatide | 197 | 28 |
| Montelukast Sodium | Montelukast Sodium | 174 | 49 |
| Furosemide | Furosemide | 162 | 56 |
| Escitalopram Oxalate | Escitalopram Oxalate | 160 | 37 |
| Metformin Hcl | Metformin Hcl | 155 | 45 |
| Trazodone Hcl | Trazodone Hcl | 149 | 46 |
| Tramadol Hcl | Tramadol Hcl | 148 | 39 |
| Meloxicam | Meloxicam | 141 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 141 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 138 | 54 |
| Diazepam | Diazepam | 135 | 26 |
| Alprazolam | Alprazolam | 134 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 126 | 36 |
| Sertraline Hcl | Sertraline Hcl | 126 | 36 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 113 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 111 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 110 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 110 | 33 |
| Cefdinir | Cefdinir | 108 | 80 |
| Clopidogrel | Clopidogrel Bisulfate | 104 | 31 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 102 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 100 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 97 | 30 |
| Lorazepam | Lorazepam | 96 | 31 |
| Carvedilol | Carvedilol | 95 | 30 |
| Eliquis | Apixaban | 94 | 26 |
| Telmisartan | Telmisartan | 94 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 93 | 24 |
| Simvastatin | Simvastatin | 91 | 25 |
| Glipizide | Glipizide | 90 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 89 | 17 |
| Aripiprazole | Aripiprazole | 87 | 20 |
| Ondansetron Odt | Ondansetron | 87 | 43 |
| Farxiga | Dapagliflozin Propanediol | 86 | 21 |
| Prednisone | Prednisone | 84 | 40 |
| Glipizide Er | Glipizide | 81 | 26 |
| Famotidine | Famotidine | 80 | 28 |
| Fluoxetine Hcl | Fluoxetine Hcl | 80 | 22 |
| Estradiol | Estradiol | 71 | 16 |
| Clonazepam | Clonazepam | 70 | 14 |
| Clonidine Hcl | Clonidine Hcl | 68 | 17 |
| Ezetimibe | Ezetimibe | 68 | 21 |
| Cephalexin | Cephalexin | 67 | 52 |
| Citalopram Hbr | Citalopram Hydrobromide | 66 | 20 |
| Allopurinol | Allopurinol | 64 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 64 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 62 | 17 |
| Azithromycin | Azithromycin | 54 | 42 |
| Donepezil Hcl | Donepezil Hcl | 54 | 14 |
| Linzess | Linaclotide | 54 | 19 |
| Baclofen | Baclofen | 53 | 12 |
| Ozempic | Semaglutide | 53 | 16 |
| Atenolol | Atenolol | 52 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 18 |
| Celecoxib | Celecoxib | 50 | 22 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 50 | 40 |
| Diclofenac Sodium | Diclofenac Sodium | 50 | 14 |
| Lidocaine | Lidocaine | 48 | 12 |
| Buspirone Hcl | Buspirone Hcl | 47 | 15 |
| Finasteride | Finasteride | 47 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 47 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 45 | 38 |
| Pregabalin | Pregabalin | 44 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 41 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 41 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | 13 |
| Temazepam | Temazepam | 40 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 39 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 31 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 38 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 36 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 34 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | 14 |
| Fluconazole | Fluconazole | 33 | 20 |
| Valacyclovir | Valacyclovir Hcl | 33 | 13 |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 21 |
| Irbesartan | Irbesartan | 32 | suppressed |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Glimepiride | Glimepiride | 31 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 31 | suppressed |
| Lamotrigine | Lamotrigine | 31 | suppressed |
| Methocarbamol | Methocarbamol | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Lovastatin | Lovastatin | 30 | suppressed |
| Spironolactone | Spironolactone | 30 | 12 |
| Bumetanide | Bumetanide | 29 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 29 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 29 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 27 | suppressed |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 26 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 20 |
| Jardiance | Empagliflozin | 25 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Gemfibrozil | Gemfibrozil | 24 | suppressed |
| Nystatin | Nystatin | 24 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Ibuprofen | Ibuprofen | 23 | 12 |
| Ketoconazole | Ketoconazole | 23 | 18 |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Sotalol | Sotalol Hcl | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 15 |
| Colchicine | Colchicine | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 16 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 19 | 12 |
| Mupirocin | Mupirocin | 19 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Testosterone | Testosterone | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Metolazone | Metolazone | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | 12 |
| Topiramate | Topiramate | 17 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Progesterone | Progesterone, Micronized | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 12 |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Roflumilast | Roflumilast | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 12 | suppressed |
| Dexamethasone | Dexamethasone | 12 | suppressed |
| Enbrel Sureclick | Etanercept | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 11 | suppressed |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Leflunomide | Leflunomide | 11 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Tegretol | Carbamazepine | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $900.71 · 60 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, Dexcom G6 Transmitter, FANAPT, FARXIGA, HETLIOZ, JOURNAVX, MOUNJARO, NURTEC ODT, OTEZLA, QULIPTA, REPATHA, REXULTI, SPRAVATO, UBRELVY, VRAYLAR, ZAVZPRET, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error